Longaeva Partners’s Scribe Therapeutics SCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding SCTX
BBA
Longaeva Partners's SCTX Position: Q3 2026 in Review
Longaeva Partners opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 34,034 shares worth $626K. The stake represents 0.01% of the portfolio and ranks #278 among its holdings.
63 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.
- Longaeva Partners held 34,034 shares of Scribe Therapeutics worth $626K as of Q3 2026.
- Scribe Therapeutics was a new Longaeva Partners position in Q3 2026.
- Scribe Therapeutics made up 0.01% of Longaeva Partners's portfolio in Q3 2026, its #278 holding.
- 63 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.
Based on Longaeva Partners's 13F filing for Q3 2026, filed 16 Nov 2026.